Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections

Keyphrases

• Ciprofloxacin 100%
• Pseudomonas Aeruginosa Infection 100%
• Pseudomonas Aeruginosa (P. aeruginosa) 28%
• Therapeutic Efficacy 28%
• Compromised Host 28%
• Lymphoma 14%
• Therapeutic Potential 14%
• Serratia Marcescens 14%
• Lung 14%
• CSF-1 14%
• Bacterial Strains 14%
• Soft Tissue 14%
• Combination Therapy 14%
• Skin Tissue 14%
• Enterobacter Cloacae 14%
• Septicemia 14%
• Azlocillin 14%
• Aminoglycosides 14%
• Clinical Cure 14%
• New Quinolone 14%
• Middle Ear 14%
• Host Defense Mechanisms 14%
• Therapeutic Safety 14%
• Pseudomonas Aeruginosa Pneumonia 14%
• Staphylococcus 14%
• Well Tolerated 14%
• Single Drug 14%

Immunology and Microbiology

• Pseudomonas aeruginosa 100%
• Infection 100%
• Immunocompromised Patient 33%
• Serratia marcescens 16%
• Cerebrospinal Fluid 16%
• Soft Tissue 16%
• Host Resistance 16%
• Bacterial Strain 16%
• Staphylococcus Aureus 16%
• Enterobacter Cloacae 16%
• Minimum Inhibitory Concentration 16%
• Middle Ear 16%
• Susceptibility 16%
• Bacterium 16%
• Lung 16%
• Drug Therapy 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ciprofloxacin 100%
• Pseudomonas Infection 100%
• Pseudomonas aeruginosa 28%
• Immunocompromised Patient 28%
• Infection 14%
• Staphylococcus Aureus 14%
• Combination Therapy 14%
• Serratia marcescens 14%
• Septicemia 14%
• Azlocillin 14%
• Aminoglycoside 14%
• Quinolone 14%
• Enterobacter Cloacae 14%
• Pseudomonas Pneumonia 14%
• Bacterium 14%